Invention Application
- Patent Title: ANTI COVID-19 THERAPIES USING CD40 LIGAND FUSION PROTEIN
-
Application No.: US17082994Application Date: 2020-10-28
-
Publication No.: US20210284713A1Publication Date: 2021-09-16
- Inventor: Kayvan Niazi , Jay Gardner Nelson , Annie Shin , Clifford Anders Olson , Shiho Tanaka
- Applicant: ImmunityBio, Inc.
- Applicant Address: US CA Culver City
- Assignee: ImmunityBio, Inc.
- Current Assignee: ImmunityBio, Inc.
- Current Assignee Address: US CA Culver City
- Main IPC: C07K14/705
- IPC: C07K14/705 ; C07K14/005 ; C12N15/86 ; A61K39/215
Abstract:
Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity comprises a nucleic acid that encodes a extracellular portion of CD40 ligand (CD40L) coupled by a flexible linker to a coronavirus 2 (CoV2) spike protein and/or a CoV2 nucleocapsid protein.
Information query
